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Abstract
Objectives—To determine the medical costs of laboratory-confirmed rotavirus hospitalizations 
and emergency department (ED) visits and estimate the economic impact of the rotavirus vaccine 
program.
Patients and methods—During 4 rotavirus seasons (2006–2009), children <3 years of age 
hospitalized or seen in the ED with laboratory-confirmed rotavirus were identified through active 
population-based rotavirus surveillance in three US counties. Medical costs were obtained from 
hospital and physician billing data, and factors associated with increased costs were examined. 
Annual national costs were estimated using rotavirus hospitalization and ED visit rates and 
medical costs for rotavirus hospitalizations and ED visits from our surveillance program for pre- 
(2006–2007) and post-vaccine (2008–2009) time periods.
Results—Pre-vaccine, for hospitalizations, the median medical cost per child was $3581, the 
rotavirus hospitalization rate was 22.1/10,000, with an estimated annual national cost of $91 
million. Post-vaccine, the median medical cost was $4304, the hospitalization rate was 6.3/10,000 
and the estimated annual national cost was $31 million. Increased costs were associated with study 
site, age <3 months, underlying medical conditions and an atypical acute gastroenteritis 
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presentation. For ED visits, the pre-vaccine median medical cost per child was $574, the ED visit 
rate was 291/10,000 resulting in an estimated annual national cost of $192 million. Post-vaccine, 
the median medical cost was $794, the ED visit rate was 71/10,000 with an estimated annual 
national cost of $65 million.
Conclusions—After implementation of rotavirus immunization, the total annual medical costs 
decreased from $283 million to $96 million, an annual reduction of $187 million
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Rotavirus; Medical costs; Hospitalizations; Emergency department visits; NVSN
1. Introduction
Prior to implementation of the rotavirus immunization program in United States (US), 
rotavirus was the most common cause of severe gastroenteritis in young children resulting in 
55,000–70,000 hospitalizations, and 205,000–272,000 emergency department (ED) visits 
each year with estimated medical costs in children less than five years of age of $264–319 
million dollars [1–3]. The recent licensure and universal use of two rotavirus vaccines 
heighten the importance of examining the impact of the US rotavirus immunization program 
on health care costs [4].
In the past, rotavirus-associated hospitalization and ED costs have been estimated from 
administrative databases using ICD-9 codes for diarrhea, then using one of two indirect 
methods to estimate the number of rotavirus diarrhea cases [5–14]. The winter residual 
method estimates the number of rotavirus cases by comparing the number of hospitalizations 
for diarrhea during the year with the excess during the months when rotavirus gastroenteritis 
is prevalent [5]. The proportional method uses monthly proportions of rotavirus-positive 
stool samples from a large surveillance study [15] and applies these to the number of 
diarrhea-related hospitalizations. These indirect estimates may not be accurate for several 
reasons. With improvements in diagnostic testing, the proportion of rotavirus-positive 
children may be higher than reported in the past. If the rotavirus season is indistinct, the 
winter residual method would underestimate cases. Imperfect sensitivity or specificity with 
diarrhea codes may lead to inaccurate estimates of diarrhea cases. A rotavirus-specific 
ICD-9 code for rotavirus diarrhea was introduced in 1992 [7]. Studies have utilized this code 
as a direct method to estimate rotavirus disease [7–15] and compared to rotavirus active 
surveillance this code was specific, but greatly underestimated rotavirus disease in both 
hospital and outpatient settings [16,17]. To overcome these limitations, active surveillance 
studies determined the proportion of acute gastroenteritis cases due to laboratory-confirmed 
rotavirus [17–22] and estimated rates of rotavirus-associated hospitalizations and ED visits 
[19–22]. In both settings, these studies have shown the proportion of rotavirus-positive cases 
to be much higher than earlier studies. Since past cost data have also used data from these 
administrative datasets, the accuracy of these cost estimates is unclear.
Since 2006, the New Vaccine Surveillance Network (NVSN) has conducted prospective 
population-based active surveillance in three US counties to identify children with 
laboratory-confirmed rotavirus infection [20–22]. This system overcomes the limitations of 
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previous studies by examining the economic burden of hospitalizations and ED visits 
associated with laboratory-confirmed population-based rotavirus disease rates in young 
children, identifying factors leading to the most costly hospitalizations, and estimating the 
impact of the rotavirus immunization program on health care costs.
2. Methods
2.1. Study design and population
The design and methods of the NVSN active population-based surveillance program have 
been previously described [20–22]. Briefly, population-based surveillance of children <3 
years of age with vomiting or diarrhea was conducted at participating NVSN sites: 
Cincinnati Children's Hospital Medical Center (Cincinnati), Vanderbilt University Medical 
Center (Nashville), and the University of Rochester Medical Center (Rochester). 
Surveillance was conducted over four seasons: 2006 (December 2005–June 2006), 2007 
(December 2006–June 2007), 2008 (December 2007–June 2008), and 2009 (July 2008–June 
2009). Participating NVSN hospitals captured >95% of all pediatric hospital admissions in 
their respective counties, but varied in the proportion of pediatric ED visits captured 
(Hamilton County, Ohio, 95% at Cincinnati Children's Hospital Medical Center ED; 
Davidson County, Tennessee, 54% at Vanderbilt University Medical Center ED; Monroe 
County, New York, 70% at Strong Memorial ED and 25% at Rochester General ED). 
Inpatient children were enrolled five days a week while ED children were systematically 
enrolled every second to fourth day.
Children eligible for enrollment for acute gastroenteritis surveillance were <3 years of age, 
residents of the specified counties and presented with symptoms of acute gastroenteritis. 
Children were excluded if they were immunocompromised, hospitalized in the prior 4 days 
or transferred from another hospital after 48 h of admission, were never discharged from the 
hospital, had symptoms for >10 days, or had a non-infectious or other identifiable cause of 
their symptoms.
Demographic, medical, and social histories were obtained by standardized interviews of 
parents/guardians. Clinical laboratory evaluation, initial presentation, hospital course, 
underlying conditions and discharge diagnoses were obtained from medical records. 
Prematurity was defined as parental report of the child being born ≥4 weeks early. Stool 
specimens were collected from each enrolled child within 14 days of symptom onset and 
were tested using a commercial enzyme immunoassay (Rotaclone®). Only children with 
laboratory-confirmed rotavirus infection were included in this analysis.
For each laboratory-confirmed rotavirus-positive child, hospital and ED billing costs and 
physician charge data were gathered from accounting databases at each site. To ensure that 
children who had multiple encounters with providers were captured in the cost data, ED 
visits and hospitalizations that occurred within 72 h of the enrollment visit and had ICD-9 
codes consistent with acute gastroenteritis were included. Children admitted to the hospital 
through the ED were categorized as hospitalized. Children were classified into three groups: 
inpatient hospitalization, short-stay admission, or ED visit. The short-stay patients were 
children admitted for observation whose stay was generally <24 h. Costs were sorted into 
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five summary categories: diagnostics, therapeutics, room costs, medical supplies and 
physician services [23]. Since cost data were not available for physician services, charges 
were used. All costs were converted to 2009 dollars using the Medical Consumer Price 
Index.
The medical records of all hospitalized children were reviewed by an investigator at each 
site (MAS, GAW, KME) to examine factors that incurred the highest costs. Records were 
reviewed for underlying medical conditions or an atypical initial clinical presentation for 
acute gastroenteritis. An atypical presentation was defined as altered mental status, findings 
suggesting sepsis, shock, or an intra-abdominal process (including appendicitis and 
intussusception).
The Institutional Review Boards at the CDC and each participating NVSN site approved the 
study. Informed written consent was obtained from the parents/guardians of enrolled 
children.
2.2. Statistical analyses
To determine medical costs, we used univariate analysis and calculated means, standard 
deviations, medians, and 5–95th percentiles. Chi-square and Fisher's exact tests were used to 
analyze the relationships and characteristics associated with patient location. The Wilcoxon 
rank-sum and Kruskal–Wallis tests were used to determine group differences in the median 
total costs and length of hospital stays. A multivariate semi-log linear regression analysis 
was conducted to determine factors associated with increased costs. Variations in the 
logarithm costs of a rotavirus-associated hospitalization or short-stay visit were examined in 
relation to the relative variability of independent variables such as atypical presentations, 
underlying conditions, ICU requirement, age <3 months, recruitment site, and health 
insurance type. A two-sided p-value of <0.05 was considered statistically significant. All 
statistical analyses were conducted in SAS version 9.3 (SAS Institute Inc., Cary, NC).
The total costs of medically attended rotavirus (hospitalizations and ED visits) were 
estimated using median and mean costs from this study and rates of hospitalizations and ED 
visits from our population-based surveillance previously published for 2006–2008 [20–22]. 
These same methods were used to calculate the 2009 rates [20–22]. Rate estimates were 
calculated using the weighted number of laboratory-confirmed rotavirus hospitalizations 
divided by the number of children within the age cohort in the county population, as 
determined by the census. Weighting was done to account for the number of surveillance 
days, the proportion of the eligible children enrolled, and the percentage of stool samples 
collected. For the 4 year time period, 936 hospitalized children were eligible; 806 (86%) 
were enrolled; 702 (87%) had a stool specimen and 697 (99%) stool specimens were tested. 
For the emergency department, there were 1914 children eligible; 1526 (80%) were 
enrolled; 971 (64%) submitted a stool specimen and 967 (99.6%) stools were tested. To 
estimate the yearly US rotavirus disease burden, the yearly rotavirus rates (hospitalizations 
or ED) were multiplied by the total number of children residing in the US according to the 
2000 US Census estimate [10]. To estimate the cost burden, the national rotavirus rates were 
multiplied by the median cost per child.
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3. Results
During the four study seasons, 583 laboratory-confirmed rotavirus cases were detected in the 
hospital and ED settings; 278 from Cincinnati, 131 from Nashville, and 174 from Rochester. 
Cost data were not available for 15 cases: 12 cases from Nashville (7 inpatient and 5 ED) 
and 3 inpatient cases from Rochester. Deviations from the protocol resulted in the exclusion 
of 16 ED cases from Cincinnati. Of the 552 remaining rotavirus cases, 276 were inpatients, 
of whom 113 (41%) were short-stay admissions, and 276 were seen only in the ED. The 
characteristics for children hospitalized, admitted for short-stay, or seen in the ED are shown 
in Table 1. A significant difference existed overall among the 3 groups for race (p < 0.001), 
and insurance status (p < 0.001). ED patients were significantly more likely to have public 
or no insurance than children hospitalized or admitted for a short-stay visit (p = 0.007). ED 
patients were significantly less likely to be non-Hispanic white compared to children 
hospitalized or admitted for a short-stay visit (p < 0.001). Significant differences existed in 
age overall among the three groups (p < 0.001). ED children and those admitted for a short 
stay admission were more likely to be ≥3 months of age compared to hospitalized children 
(p < 0.001).
3.1. Hospitalization and Short Stay Costs Associated with Rotavirus Disease
The overall mean medical cost per rotavirus–associated hospitalization and short-stay 
admission was $5011, and $3646 respectively with a median cost of $3915 and $3474 
respectively (Fig. 1a and b). The combined hospitalization and short-stay mean cost was 
$4452 and the median cost was $3712. Of hospitalization costs, 58% of the total medical 
costs were due to hospital and ED room costs. Physician fees accounted for another 22% of 
the total hospital costs. Of short-stay admissions, room charges accounted for 62% of total 
costs and physician fees were 16% of total costs. More detailed hospitalization and short-
stay cost data can be found in Supplemental Table 1 with site-specific data in Supplemental 
Table 2.
3.2. Emergency department visit costs associated with rotavirus disease
The overall mean medical cost per rotavirus-associated ED visit was $810 with a median 
cost of $630. The majority of the costs were from room (27%) and physician fees (56%) 
while diagnostics and therapeutics represented only a small proportion (7% and 6% 
respectively) (Fig. 1c). More detailed site-specific ED cost data can be found in 
Supplemental Table 3.
3.3. Diagnostic testing and antibiotic use (Table 2)
Overall, 31% of hospitalized children were treated with antibiotics compared to 18% of 
short-stay patients and 4% of ED patients. Of patients hospitalized, 55% received 
intravenous antimicrobial therapy compared to 23% of short-stay and 5% of ED patients (p 
< 0.001).
Renal panels were frequently used for evaluating children hospitalized (88%) or admitted 
for a short-stay (81%) compared to ED patients (31%). Similarly, radiologic evaluations 
were used for 31%, 26% and 10% of children hospitalized, with short stay visits or with ED 
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visits, respectively. Overall, rotavirus testing was infrequently ordered for children 
hospitalized (48%) or admitted for a short stay (23%) and even less frequently requested for 
ED patients (3%).
3.4. Factors associated with high costs
Factors examined with increased costs for the 276 hospitalized and short-stay admissions are 
shown in Table 3. As expected, an ICU stay generated significantly greater costs than a non-
ICU stay (median cost of $13,321 versus $3657 respectively). While children with an ICU 
stay had higher individual costs, children without ICU care accounted for 91% of the total 
costs and 93% of the total bed days. Medical costs were significantly affected by age (p = 
0.001). Children <3 months of age had significantly higher costs (p < 0.001) compared to 
older children and accounted for 10% of the rotavirus-related hospitalizations and 16% of 
the total costs. In the univariate analysis, increased costs were significantly associated with 
an ICU admission (p = 0.008), race other than white/non-Hispanic (p = 0.04), insurance 
status (p = 0.02), young age (p = 0.001), an atypical presentation (p < 0.001) and study site 
(p < 0.001). In the multivariate regression analysis, factors significantly associated with 
higher costs included atypical presentation (p < 0.001), presence of an underlying condition 
(p = 0.003), age <3 months (p = 0.02) and study site (p < 0.001). For those children with an 
atypical presentation, the incremental cost was $1861 compared to those with a typical 
presentation. Children with an underlying condition had an incremental cost of $1168 
compared to those without. Children <3 months of age had an incremental cost of $1144 
compared to those ≥3 months of age. Costs were $2585 less for children from Nashville 
compared to children from Cincinnati (p < 0.001) and $2408 less for children from 
Nashville compared to Rochester (p < 0.001).
3.5. Projected national costs associated with rotavirus disease
The yearly rates of hospitalizations, median and mean costs and the estimated national costs 
are shown in Table 4. The combined 2006 and 2007, pre-vaccine rate of rotavirus-associated 
hospitalizations and short-stay visits was 22.1 per 10,000 [8] and the median cost per 
hospitalized child was $3581 (95% CI $3328–3802). Using this rotavirus hospitalization rate 
and the median cost per hospitalization and extrapolating to the US population of children 
<3 years of age [10], for the 2006 and 2007 seasons, we estimated 25,370 rotavirus-related 
hospitalizations occurred annually with $91 million (95% CI $78–104 million) in medical 
costs in 2009 US dollars. In the 2008 and 2009 post-vaccine seasons, the average rate of 
hospitalization was 6.3/10,000 and the median cost was $4304 (95% CI $3797–5018). We 
estimated there were 7191 hospitalizations due to rotavirus each year at a cost of $31 million 
(95% CI $21–42 million). Comparing the pre- and post-vaccine periods, after implementing 
the rotavirus immunization program in the US, there was a decrease of $120 million in costs 
for rotavirus-associated hospitalizations for the two-year period.
For ED visits, in the pre-vaccine period, the overall median cost was $574 (95% CI $539–
645). Using the 2006 and 2007 ED visit rate of 291/10,000, the median costs of an ED visit 
and extrapolating to the US population of children <3 years of age [24], there were an 
estimated 334,810 rotavirus-related ED visits annually with estimated annual medical costs 
of $192 million in 2009 US dollars. In the post-vaccine period, the average annual rotavirus-
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associated ED visit rate was 71 per 10,000 and the median cost per child per ED visit was 
$794 (95% CI $669–909) with an estimated annual cost of $65 million. Comparing the pre- 
and post-vaccine periods, there was a decrease of $254 million in costs for rotavirus-
associated ED visits for the two-year period.
4. Discussion
To our knowledge, this is the first population-based study utilizing active surveillance with 
laboratory-confirmed rotavirus cases and billing data to determine medical costs associated 
with rotavirus-associated hospitalizations and ED visits. Our national estimate of rotavirus 
hospitalization costs of $93 million in 2006 (adjusted to 2009 dollars) is less than previously 
reported unadjusted costs of $150–198 million [1–3] and is far less than the adjusted costs of 
$190–289 million. This difference is primarily due to the lower national estimate of 25,887 
rotavirus hospitalizations in our study compared with previous estimates of 55,000–70,000. 
The differences in our direct estimates and previously published indirect estimates are likely 
due to the methods used for identifying children with rotavirus. The indirect method 
estimated more children hospitalized with rotavirus compared to our direct method. This 
could be due to including children who developed diarrhea after their admission or by 
overestimating the proportion of acute gastroenteritis cases due to rotavirus. For children 
seen in the ED, the indirect method likely underestimates ED-associated rotavirus visits 
since diagnoses such as dehydration, vomiting and viral illness are not included for 
identification of children with acute gastroenteritis. In addition, the indirect estimate used a 
much lower proportion of rotavirus-positive acute gastroenteritis compared to active 
surveillance estimates with laboratory-confirmed rotavirus, thus underestimating the total 
number of rotavirus-associated ED visits. Our pre-licensure median cost of ~$3581 was 
higher than the median cost of $2962 in the Widdowson study [3]. The costs for the 
Widdowson study were based on a two day hospitalization for rotavirus gastroenteritis using 
the rotavirus-specific ICD-9-CM code [3] while our costs were based on actual costs of 
children hospitalized for rotavirus. Another potential reason for the differences is that our 
surveillance program identified children presenting with symptoms of acute gastroenteritis 
and did not include children with nosocomial rotavirus infections, which may represent up 
to 20% of all rotavirus cases in hospitalized children [25]. A simple inflation of our costs by 
20% to account for the number of children with nosocomial infections is unlikely to 
accurately reflect the total costs attributed to rotavirus in this group of children with 
nosocomial disease since these children may have more complex medical issues and higher 
costs for their rotavirus-associated illness. With that said, if we use the same median costs/
case as our community-associated cases and assume a 20% increase in the number of 
hospitalizations, the average pre-licensure cost per year would be $108,946,117. In addition, 
our study included children <3 years of age while other studies included children <5 years of 
age. If we conservatively increase the number of children hospitalized by 10% to account for 
this broader age range in addition to the increase for nosocomial infections, the cost per year 
pre-licensure, would be $118,024,960. If there was a 40% increase due to nosocomial cases 
and age differences, the average costs per year pre-licensure would be $127,103,803. We 
included short-stay admissions as hospitalizations while administrative database studies 
include short-stay visits as ED visits. Short-stay visits increased the number of 
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hospitalizations in our estimates, but these admissions did have a lower median cost 
compared to hospitalized children. Since national estimates of the proportion of children 
cared for as short-stay admissions is not known, it is difficult to assess how this would affect 
estimates from administrative databases.
Since the implementation of the rotavirus vaccine program, we demonstrated a 66% 
decrease in the costs of US rotavirus hospitalizations. Similarly, another study examining 
decreased rotavirus vaccine and health care utilization for diarrhea in US children <5 years 
of age using MarketScan data, found a reduction of 64,855 hospitalizations due to diarrhea 
(not specifically rotavirus) in the 2007–2009 time period with a savings of $278 million in 
treatment costs [13]. Comparing these estimates directly is difficult given methodological 
differences. However, both studies, found a dramatic decrease in diarrhea-associated 
hospitalization costs after rotavirus vaccine introduction. Given the post-licensure, biennial 
rotavirus activity seen in our study and others [13,26,27], it will be important to take this 
into account when examining the economic impact of the rotavirus vaccine program.
In our study, we found higher cost hospitalizations were significantly associated with study 
site, younger age (<3 months), atypical clinical presentation, and presence of an underlying 
condition. By using sensitive, rapid and effective techniques for evaluation and diagnosis of 
rotavirus there could be further cost-savings by reducing unnecessary testing and antibiotic 
use.
In contrast to the pre-vaccine hospitalization estimates, our national ED cost estimates of 
$192 million annually were significantly higher than previous unadjusted estimates of $37–
71 million, even after adjusting for 2009 dollars ($61–86 million) [1–3]. This difference was 
driven by both higher estimates of ED visits and costs in our study compared with previous 
studies. Prior studies estimated 20–28% of ED visits for diarrhea were due to rotavirus. 
However, our study found 37–49% of children with acute gastroenteritis in the ED have 
rotavirus [17,19,20,22]. In addition, the Widdowson study used a median cost of $332 which 
was much lower than our pre-licensure median ED cost of $574. This may be due to the use 
of diarrhea-specific ICD-9 codes to determine the ED costs [1–3]. These codes do not 
include codes for vomiting, dehydration or viral illness, which could result in not only an 
underestimation of acute gastroenteritis cases but also more severe cases of acute 
gastroenteritis with significant dehydration. There could also be shifts from inpatient to ED 
management which would also increase the number of ED visits and decrease the number of 
hospitalizations compared to past years [28]. In our study, we did see a significantly higher 
median cost for ED cases post-licensure compared to pre-licensure ED costs.
Among the limitations of our study is that despite conducting population-based surveillance 
for four seasons at three sites, our study was limited to community-acquired rotavirus in 
immuno-competent children in urban areas. Our results are likely to be representative of 
similarly sized counties in the United States. Our study also used unadjusted physician 
charges, which may overestimate total medical costs by approximately 6–14% [29]. Lastly, 
a possible limitation is that 16 cases were excluded for protocol deviations from Cincinnati 
and 15 cases from the other sites for missing cost data. Most of these children were ED 
cases so there was little variation in their costs compared to cases with available data. For 
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hospitalized children with missing data, the lengths of stay for Cincinnati and Rochester 
inpatients were not significantly different compared to those included from their respective 
sites. However, the 7 hospitalized children from Nashville with missing data had a 
significantly longer length of stay compared to those in the study. Not including these 
children may have contributed to the overall lower costs for Nashville.
5. Conclusions
Costs for rotavirus hospitalizations and ED visits accounted for a significant economic 
burden in the US. Although our cost estimates for hospitalizations were lower compared to 
previous studies, our ED visit costs were much higher than previously estimated. There has 
been a dramatic decline in rotavirus-associated hospitalization and ED visit costs since the 
widespread use of rotavirus vaccine in the US with an estimated annual savings of $187 
million dollars in health care costs.
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Fig. 1. 
(a) Medical costs for rotavirus-associated hospitalizations proportion and median costs (95% 
confidence intervals) by cost category overall median cost for rotavirus-associated 
hospitalization: $3915 ($3655, $4340). (b) Medical costs for rotavirus-associated short-stay 
visits proportion and median costs (95% confidence intervals) by cost category overall 
median cost for rotavirus-associated short-stay visit: $3474 ($3655, $4340). (c) Medical 
costs for rotavirus-associated emergency department visits proportion and median costs 
(95% confidence intervals) by cost category overall median cost for rotavirus-associated ED 
visits: $630 ($575, $690).
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Table 1
Characteristics of children with rotavirus-associated hospital, short-stay and emergency department visits, 
2006-2009.
Total N = 552 Hospitalized
n = 163 (30%)
n (%)
Short stay
n = 113 (20%)
n (%)
Emergency department
n = 276 (50%)
n (%)
p-Value
Gender
    Male 76 (47) 55 (49) 151 (55) 0.22
    Female 87 (53) 58 (51) 125 (45)
Ethnicity/racea
    White/non-Hispanic 91 (56) 69 (62) 105 (38) <0.001
    Black/non-Hispanic 36 (22) 34 (30) 99 (36)
    Other 35 (22) 9(8) 69 (25)
Insuranceb
    Private 76 (47) 61 (54) 105 (38) 0.02
    Public 79 (49) 42 (37) 143(52)
    None 7 (4) 10(9) 26 (9)
Age in months
    <3 24 (15) 4 (4) 7 (3) <0.001
    3–5 4(2) 12 (11) 20 (7)
    6–11 22 (13) 18 (16) 62 (22)
    12–17 40 (25) 27 (24) 64 (23)
    18–23 34 (21) 21 (19) 66 (24)
    24–35 39 (24) 31 (27) 57 (21)
Bold values indicate a statistically significant difference between columns.
a5 children's race is unknown (1 inpatient, 1 short-stay patient and 3 ED patients).
b3 children's insurance type is unknown (1 inpatient and 2 ED patients).
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Table 2
Overall proportion of children by visit type with antibiotic use, renal panel, radiographs and rotavirus testing.
Hospitalized
N =163
Short-stay
N=113
ED
N=276
n % n % n %
Antibioticsa,b,c 50 31 20 18 11 4
Renal paneld,e 143 88 92 81 86 31
Radiographf,g 50 31 29 26 27 10
Rotavirus testh,i,j 79 48 26 23 8 3
a
Hospitalized vs. short stay p-value = 0.01.
b
Hospitalized vs. ED p-value < 0.001.
cShort-stay vs. ED p-value < 0.001.
d
Hospitalized vs. ED p-value < 0.001.
eShort-stay vs. ED p-value < 0.001.
f
Hospitalized vs. ED p-value < 0.001.
gShort-stay vs. ED p-value < 0.001.
h
Hospitalized vs. short stay p-value < 0.001.
i
Hospitalized vs. ED p-value < 0.001.
jShort-stay vs. ED p-value < 0.001.
Vaccine. Author manuscript; available in PMC 2015 November 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kilgore et al. Page 15
Ta
bl
e 
3
U
ni
va
ria
te
 a
na
ly
sis
 o
f e
sti
m
at
ed
 m
ed
ic
al
 c
os
ts 
an
d 
LO
S 
fo
r c
om
bi
ne
d 
ro
ta
vi
ru
s-
as
so
ci
at
ed
 h
os
pi
ta
liz
at
io
ns
 a
nd
 sh
or
t-s
ta
y 
vi
sit
s, 
20
06
–2
00
9.
H
os
pi
ta
l c
os
ts
Le
ng
th
 o
f s
ta
y
N
M
ea
n
M
ed
ia
n
5-
95
th
 p
er
ce
nt
ile
s
p-
V
al
ue
Pe
rc
en
t o
f c
os
t
N
M
ea
n
M
ed
ia
n
R
an
ge
p-
V
al
ue
To
ta
l b
ed
 d
ay
s
Pe
rc
en
t t
ot
al
 b
ed
 d
ay
s
IC
U
 
 
 
 
N
o
26
8
$4
18
0
$3
65
7
(14
30
–8
08
5)
0.
00
8
91
%
26
8
2
1
(0–
12
)
0.
00
2
42
4
93
%
 
 
 
 
Y
es
8
$1
3,5
66
$1
3,3
21
(55
98
–2
2,6
31
)
9%
8
4
3
(2–
7)
30
7%
Pr
em
at
ur
ity
 
 
 
 
N
o
25
2
$4
46
5
$3
71
2
(16
91
–9
18
0)
0.
99
92
%
25
2
2
1
(0–
12
)
0.
46
41
8
92
%
 
 
 
 
Y
es
24
$4
31
6
$3
61
4
(12
00
–7
87
2)
8%
24
2
1
(0–
5)
36
8%
G
en
de
r
 
 
 
 
M
al
e
13
1
$4
27
2
$3
70
8
(12
48
–8
53
3)
0.
92
46
%
13
1
2
1
(0–
6)
0.
63
21
3
47
%
 
 
 
 
Fe
m
al
e
14
5
$4
61
4
$3
75
2
(17
62
–9
41
1)
54
%
14
5
2
1
(0–
12
)
24
1
53
%
R
ac
ea
 
 
 
 
O
th
er
11
4
$4
86
3
$3
93
9
(14
30
–1
0,9
24
)
0.
04
45
%
11
4
2
2
(0–
7)
0.
02
20
7
46
%
 
 
 
 
W
hi
te
/n
on
-H
isp
an
ic
16
0
$4
19
4
$3
51
2
(15
68
–7
75
9)
55
%
16
0
2
1
(0–
12
)
24
5
54
%
Pr
iv
at
e 
in
su
ra
nc
eb
 
 
 
 
N
o
13
8
$4
83
7
$3
95
4
(13
53
–1
0,5
11
)
0.
02
54
%
13
8
2
1
(0–
12
)
0.
16
24
4
54
%
 
 
 
 
Y
es
13
7
$4
07
1
$3
54
3
(14
45
–8
47
3)
46
%
13
7
2
1
(0–
6)
20
9
46
%
A
ge
 g
ro
up
 (m
on
ths
)
 
 
 
 
<
3
28
$7
15
4
$5
22
7
(24
29
–2
2,6
31
)
0.
00
1
16
%
28
3
2
(0–
12
)
0.
03
71
16
%
 
 
 
 
3–
5
16
$4
60
3
$4
51
3
(11
14
–9
65
0)
6%
16
2
1
(0–
6)
28
6%
 
 
 
 
6–
11
40
$4
16
0
$3
75
1
(14
46
–8
13
7)
14
%
40
2
2
(0–
4)
65
14
%
 
 
 
 
12
–1
7
67
$3
74
5
$3
43
4
(12
48
–6
90
5)
20
%
67
1
1
(0–
5)
99
22
%
 
 
 
 
18
–2
3
55
$4
52
8
$3
50
9
(14
45
–1
2,4
00
)
20
%
55
2
1
(0–
6)
86
19
%
 
 
 
 
24
–3
5
70
$4
12
1
$3
62
4
(18
20
–8
53
3)
23
%
70
2
1
(0–
6)
10
5
23
%
U
nd
er
ly
in
g 
co
nd
iti
on
 
 
 
 
N
o
23
8
$4
26
8
$3
65
7
(14
30
–8
47
3)
0.
16
83
%
23
8
2
1
(0–
12
)
0.
13
36
9
81
%
 
 
 
 
Y
es
38
$5
60
6
$4
44
0
(73
3–
19
,27
7)
17
%
38
2
2
(0–
7)
85
19
%
A
ty
pi
ca
l p
re
se
nt
at
io
n
 
 
 
 
N
o
22
7
$3
83
8
$3
47
4
(13
53
–7
20
1)
<
0.
00
1
71
%
22
7
1
1
(0–
7)
0.
00
6
33
3
73
%
Vaccine. Author manuscript; available in PMC 2015 November 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kilgore et al. Page 16
H
os
pi
ta
l c
os
ts
Le
ng
th
 o
f s
ta
y
N
M
ea
n
M
ed
ia
n
5-
95
th
 p
er
ce
nt
ile
s
p-
V
al
ue
Pe
rc
en
t o
f c
os
t
N
M
ea
n
M
ed
ia
n
R
an
ge
p-
V
al
ue
To
ta
l b
ed
 d
ay
s
Pe
rc
en
t t
ot
al
 b
ed
 d
ay
s
 
 
 
 
Y
es
49
$7
29
6
$5
49
1
(25
82
–1
9,2
77
)
29
%
49
2
2
(0–
12
)
12
1
27
%
Si
te
 
 
 
 
Ci
nc
in
na
ti
11
8
$5
25
5
$4
23
9
(22
90
–1
0,9
24
)
<
0.
00
1
50
%
11
8
2
1
(0–
12
)
<
0.
00
1
19
0
42
%
 
 
 
 
N
as
hv
ill
e
62
$2
70
0
$2
58
1
(74
6–
51
12
)
14
%
62
1
1
(0–
4)
75
17
%
 
 
 
 
R
oc
he
ste
r
96
$4
59
7
$3
83
5
(22
77
–9
63
4)
36
%
96
2
2
(0–
7)
18
9
42
%
B
ol
d 
va
lu
es
 in
di
ca
te
 a
 st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
ca
te
go
rie
s.
a
2 
ch
ild
re
n 
ar
e 
un
kn
ow
n 
fo
r r
ac
e.
b 1
 c
hi
ld
 is
 u
nk
no
w
n 
fo
r i
ns
ur
an
ce
.
Vaccine. Author manuscript; available in PMC 2015 November 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kilgore et al. Page 17
Ta
bl
e 
4
(a)
 E
sti
ma
ted
 na
tio
na
l a
nn
ua
l c
os
ts 
for
 ro
tav
iru
s h
os
pit
ali
za
tio
ns
 in
 th
e U
nit
ed
 St
ate
s, 
(b)
 E
sti
ma
ted
 na
tio
na
l a
nn
ua
l c
os
ts 
for
 em
erg
en
cy
 de
pa
rtm
en
t (
ED
) 
v
isi
ts 
in
 th
e 
U
ni
te
d 
St
at
es
.
(a)
 H
os
pit
ali
za
tio
ns
Se
as
on
R
at
e 
pe
r 
10
,0
00
N
um
be
r o
f h
os
pi
ta
liz
at
io
ns
M
ed
ia
n 
co
st
H
os
pi
ta
l c
os
ts
 (9
5%
 C
I)
M
ea
n 
co
st
H
os
pi
ta
l c
os
ts
 (9
5%
 C
I)
20
06
22
.5
 (1
9.2
–2
5.7
)
25
,8
87
S3
59
2
$9
2,9
81
,17
0 (
$7
9,3
43
,93
2, 
$1
06
,20
5,1
59
)
$4
15
9
$1
07
,66
5,3
94
 ($
91
,87
4,4
70
, $
12
2,9
77
,80
6)
20
07
21
.6
 (1
8.5
–2
4.6
)
24
,8
52
$3
56
5
$8
8,5
95
,86
9 (
$7
5,8
80
,72
2, 
$1
00
,90
0,8
51
)
$4
25
7
$1
05
,79
4,2
58
 ($
90
,61
0,8
23
, $
12
0,4
87
,90
5)
20
08
2.
4 
(1.
0–
4.1
)
27
61
$4
29
7
$1
1,8
66
,13
5 (
$4
94
4,2
23
, $
20
,27
1,3
14
)
$4
65
1
$1
2,8
42
,87
6 (
$5
,35
1,1
98
, $
21
,93
9,9
13
)
20
09
10
.1
 (7
.6–
12
.7)
11
,6
21
$4
31
1
$5
0,0
91
,58
8 (
$3
7,6
92
,68
0, 
$6
2,9
86
,45
3)
$5
34
6
$6
2,1
23
,37
3 (
$4
6,7
46
,30
0, 
$7
8,1
15
,52
8)
(b
) E
me
rg
en
cy
 de
pa
rtm
en
t v
isi
ts
Se
as
on
R
at
e 
pe
r 
10
,0
00
N
um
be
r o
f E
D
 v
isi
ts
M
ed
ia
n 
co
st
 (9
5%
 C
I)
ED
 c
os
ts
M
ea
n 
co
st
 (9
5%
 C
I)
ED
 c
os
ts
20
06
30
1.
0
34
6,
31
5
$5
43
 ($
37
9, 
$5
75
)
$1
87
,92
0,6
53
$5
86
 ($
45
2, 
$7
21
)
$2
02
,94
0,5
38
20
07
28
1.
0
32
3,
30
4
$7
24
 ($
55
4, 
$8
23
)
$2
34
,10
5,5
57
$8
86
 ($
76
5–
$1
00
6)
$2
86
,44
7,3
03
20
08
44
.2
50
,8
54
$5
40
 ($
50
3, 
$8
73
)
$2
7,4
69
,88
6
$6
28
 ($
47
0, 
$7
86
)
$3
1,9
36
,44
8
20
09
97
.8
11
2,
52
4
$8
27
 ($
67
2, 
$9
61
)
$9
3,0
15
,36
9
$9
92
 ($
83
4, 
$1
15
0)
$1
11
,62
3,3
94
Vaccine. Author manuscript; available in PMC 2015 November 19.
